Adjuvant Imatinib for High-Risk GI Stromal Tumor: Analysis of a Randomized Trial - Concepedia

Concepedia

Publication | Closed Access

Adjuvant Imatinib for High-Risk GI Stromal Tumor: Analysis of a Randomized Trial

225

Citations

23

References

2015

Year

Heikki Joensuu, Mikael Eriksson, Kirsten Sundby Hall, Annette Reichardt, Jörg T. Hartmann, Daniel Pink, Giuliano Ramadori, Peter Hohenberger, Salah‐Eddin Al‐Batran, M. Schlemmer,

Journal of Clinical Oncology

Abstract

Three years of adjuvant imatinib therapy results in longer survival than 1 year of imatinib. High 5-year survival rates are achievable in patient populations with high-risk GIST.

References

	Year	Citations

Page 1